{"id":"W4306409947","doi":"10.1038/s41591-022-02076-8","title":"Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial","year":2022,"lang":"en","type":"erratum","venue":"Nature Medicine","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"Toronto Western Hospital; Ottawa Hospital; Parkwood Institute; University of Ottawa; University Health Network; University of Toronto","funders":"","keywords":"Progressive supranuclear palsy; Placebo; Medicine; Monoclonal antibody; Randomized controlled trial; Internal medicine; Antibody; Pathology; Disease; Immunology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008513657,0.002502369,0.003486617,0.002417045,0.002253301,0.003103914,0.003670663,0.009192768,0.03662438],"category_scores_gemma":[0.0867499,0.00138985,0.002706637,0.001932303,0.001902831,0.00151864,0.001155385,0.01027216,0.01571898],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005039235,"about_ca_system_score_gemma":0.006471275,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01547114,"about_ca_topic_score_gemma":0.01701078,"domain_scores_codex":[0.9941397,0.001466778,0.001199495,0.0007454162,0.002078959,0.0003697876],"domain_scores_gemma":[0.9662312,0.01479165,0.002668502,0.001627854,0.01329886,0.00138195],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.0002258035,0.000009648741,0.00006568538,0.0003194146,0.00005500537,0.0002416604,0.00001366021,0.00002801606,0.00003469278,0.0002527218,0.9951321,0.00362157],"study_design_scores_gemma":[0.003384456,0.0002015557,0.002186319,0.00245672,0.0008810264,0.001557518,0.0001009879,0.0006115517,0.000823389,0.002009733,0.9856618,0.0001249608],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"editorial","genre_gemma":"other","genre_scores_codex":[0.0001883918,0.002252924,0.0003879305,0.05713028,0.937083,0.00008790359,0.001204352,0.0001828739,0.001482323],"genre_scores_gemma":[0.02019281,0.01313259,0.005480155,0.3031964,0.502755,0.001065555,0.00250088,0.001410386,0.1502661],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.03662438,"threshold_uncertainty_score":0.1225207,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0102710263310345,"score_gpt":0.3305607861555885,"score_spread":0.320289759824554,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}